Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

• Imatinib mesylate is considered standard of care for first-line treatment of chronic phase chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International Randomized Study of Interferon vs STI571 (IRIS) trial, previously untreated CML-CP patients were randomized to imatinib (n=553) or interferon-alpha (IFN) plus cytarabine (n=553). This 6-year update focuses on patients randomized to receive imatinib as first-line therapy for newly diagnosed CML-CP. During the sixth year of study treatment, there were no reports of disease progression to accelerated phase (AP) or blast crisis (BC). The toxicity profile was unchanged. The cumulative best complete cytogenetic response (CCyR) rate was 82%; 63% of all patients randomized to receive imatinib and still on study treatment showed CCyR at last assessment. The estimated event-free survival at 6 years was 83%, and the estimated rate of freedom from progression to AP and BC was 93%. The estimated overall survival was 88% -- or 95% when only CML-related deaths were considered. This 6-year update of IRIS underscores the efficacy and safety of imatinib as first-line therapy for patients with CML.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Keyword

Benzamides

Disease Progression

Follow-Up Studies

Heart Failure

chemically induced

Humans

Leukemia

Myelogenous

Chronic

BCR-ABL Positive

complications

drug therapy

mortality

Neoplasms

Second Primary

chemically induced

Piperazines

administration & dosage

toxicity

Pyrimidines

administration & dosage

toxicity

Remission Induction

Survival Analysis

Treatment Outcome

Publication and Content Type

ref (subject category)

art (subject category)